Akari Therapeutics (NASDAQ:AKTX) Now Covered by StockNews.com

StockNews.com began coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a report published on Wednesday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Akari Therapeutics Price Performance

AKTX opened at $1.35 on Wednesday. The stock has a fifty day moving average of $1.17 and a 200-day moving average of $2.44. Akari Therapeutics has a fifty-two week low of $0.90 and a fifty-two week high of $4.40.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.